Illumina (NASDAQ:ILMN) Reaches New 1-Year High – Here’s What Happened

Shares of Illumina, Inc. (NASDAQ:ILMN) hit a new 52-week high during trading on Thursday . The company traded as high as $198.10 and last traded at $198.7910, with a volume of 112974 shares traded. The stock had previously closed at $190.87.

Analyst Ratings Changes

A number of analysts have recently issued reports on ILMN shares. Leerink Partners boosted their price objective on Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a research report on Friday, July 17th. Guggenheim raised their target price on Illumina from $180.00 to $200.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. TD Cowen reiterated a “hold” rating on shares of Illumina in a research note on Wednesday, July 15th. Sanford C. Bernstein initiated coverage on shares of Illumina in a report on Friday, June 26th. They issued a “market perform” rating and a $185.00 price target on the stock. Finally, Wall Street Zen lowered shares of Illumina from a “buy” rating to a “hold” rating in a report on Saturday, July 18th. Nine analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $156.88.

Illumina Trading Up 3.4%

The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. The company has a 50 day moving average of $169.14 and a 200 day moving average of $144.62. The firm has a market cap of $29.87 billion, a price-to-earnings ratio of 35.79, a price-to-earnings-growth ratio of 2.84 and a beta of 1.47.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The business had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter last year, the company posted $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, research analysts anticipate that Illumina, Inc. will post 5.22 EPS for the current year.

Insiders Place Their Bets

In related news, Director Keith A. Meister sold 235,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $163.63, for a total value of $38,453,050.00. Following the completion of the sale, the director owned 2,830,452 shares of the company’s stock, valued at $463,146,860.76. This trade represents a 7.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Scott D. Ericksen sold 500 shares of Illumina stock in a transaction on Friday, May 29th. The shares were sold at an average price of $160.00, for a total value of $80,000.00. Following the completion of the sale, the chief accounting officer directly owned 14,446 shares of the company’s stock, valued at $2,311,360. This trade represents a 3.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,003,769 shares of company stock worth $155,710,908 over the last ninety days. Company insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Illumina

Several institutional investors have recently modified their holdings of ILMN. Impact Partnership Wealth LLC raised its holdings in shares of Illumina by 235.8% in the first quarter. Impact Partnership Wealth LLC now owns 11,080 shares of the life sciences company’s stock valued at $1,366,000 after purchasing an additional 7,780 shares during the last quarter. SG Americas Securities LLC grew its position in shares of Illumina by 8.0% in the 1st quarter. SG Americas Securities LLC now owns 86,318 shares of the life sciences company’s stock valued at $10,640,000 after acquiring an additional 6,425 shares during the period. Louisiana State Employees Retirement System acquired a new position in shares of Illumina during the 1st quarter worth about $5,460,000. VIRGINIA RETIREMENT SYSTEMS ET Al raised its holdings in shares of Illumina by 27.4% in the 4th quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 348,011 shares of the life sciences company’s stock valued at $45,645,000 after purchasing an additional 74,900 shares during the period. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in shares of Illumina by 15.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 105,237 shares of the life sciences company’s stock valued at $13,803,000 after purchasing an additional 14,072 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.